Technical Data
I7662-16
Interferon gamma, Recombinant, Human (IFNg)
100ug
|
Technical Data |
|
I7662-16 |
Interferon gamma, Recombinant, Human (IFNg) |
100ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Interferon-gamma (IFN-g) is a lymphoid factor which possesses potent anti-viral activity. It has also been shown to stimulate macrophages and NK cells. Human IFN-g is a 16.7kD protein. Interferon gamma is the only known type II interferon. Under physiological conditions, interferon gamma is induced when T-lymphocytes, previously sensitized to an antigen, are exposed to the same antigen, hence its other name: immune interferon. IFNg is produced by lymphocytes expressing the surface antigens CD4 and CD8. The synthesis of IFN-gamma is induced, among other things, by Interleukin-2 , FGF-basic and EGF. Interferon gamma has demonstrated significant anti-proliferative effects in in vivo studies; however, its therapeutic effects have been limited. Endogenous IFN-g has been shown to be required for the protection of mice against mycobacteri and leishmaniasis. In the U.S., human IFN-g has been approved for reducing the frequency and severity of infections in patients with chronic granulomatous disease. Recombinant Human Interferon gamma produced in E. coli is a single, non-glycosylated, polypeptide chain containing 144 amino acids and having a molecular mass of 16.879kD. Biological Activity: Biological Activity: IFNg is fully biologically active when compared to standard. The specific activity as determined in a viral resistance assay is <0.05ng/ml, corresponding to a specific activity of 2.0x10e7 IU/mg. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 0.640 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of IFN-gamma as a Reference Standard. Amino Acid Sequence: MQDPYVKEAE NLKKYFNAGH SDVADNGTLF LGILKNWKEE SDRKIMQSQI VSFYFKLFKN FKDDQSIQKS VETIKEDMNV KFFNSNKKKR DDFEKLTNYS VTDLNVQRKA IHELIQVMAE LSPAAKTGKR KRSQMLFQGR RASQ Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, 0.1% HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: 16.879kD |
Source: E. coli Purity: >95% by RP-HPLC and SDS-PAGE. Chromatographically purified. Form: Supplied as a lyophilized powder in 10mM sodium phosphate buffer, pH 7.4. Reconstitute in sterile dH2O, 0.1% HSA or BSA to a concentration 0.1mg/ml. Can be further diluted to other aqueous solutions. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
|
1. Rubinstein, S., Familletti, P.C., Pestka, S.: Convenient Assay for Interferons. J. Virol. 37: 755-758 (1981). 2. Familletti, P. C., Rubinstein, S., Pestka, S.: A Convenient and Rapid Cytopathic Effect Inhibition Assay for Interferon. Methods in Enzymology 78: 387-394 (1981). 3. Discrimination of Acute Graft-versus-Host Disease from Infections by Enumeration of Peripheral Blood Interferon-gamma Spot-Forming Cells. Transplantation 2006 Feb 27;81(4):632-635 4. Determination of the Functional Status of Alloreactive T Cells by Interferon-gamma Kinetics. Transplantation 2006 Feb 27;81(4):590-8 5. Human Allograft Arterial Injury Is Ameliorated by Sirolimus and Cyclosporine and Correlates with Suppression of Interferon-gamma. Transplantation 2006 Feb 27;81(4):559-566 6. Astragaloside IV Exerts Antiviral Effects Against Coxsackievirus B3 by Upregulating Interferon-gamma. J Cardiovasc Pharmacol 2006 Feb;47(2):190-195 7. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet 2006 Feb 22;
|
||